Dapagliflozin Suppressed Cuproptosis and Myocardial Fibrosis in Myocardial Infarction Through HIF-1α/TGF-β Pathway

Abstract

Background

Myocardial infarction (MI) and postmyocardial remodeling are the most common causes of heart failure worldwide and seriously affect the quality of life and prognosis of patients. Dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, is a novel class of hypoglycemic drug that has been proven to have cardiovascular protective effects. However, the underlying mechanisms by which dapagliflozin affects MI have yet to be elucidated.

Methods

An MI mouse model was created by ligating the left anterior descending branch of the coronary artery. Hematoxylin‒eosin (HE) and Masson’s trichrome (Masson) staining were used to assess myocardial damage. The levels of fibrosis-related and cuproptosis-related markers were assessed via Western blot analysis. A hypoxia-induced cardiomyocyte fibrosis model was constructed in vitro. The DCFH-DA probe was used to measure the levels of reactive oxygen species (ROS), and flow cytometry was used to identify cell apoptosis.

Results

Dapagliflozin improved heart function, ameliorated fibrosis in the myocardium, and alleviated myocardial injury. Moreover, dapagliflozin reduced the copper ion concentration and ROS accumulation and inhibited the expression of cuproptosis-related markers. Dapagliflozin suppressed the expression of HIF-1α/TGF-β signal and the overexpression of HIF-1α effectively reversed the dapagliflozin-mediated myocardial protective effects.

Conclusion

Dapagliflozin reduced myocardial fibrosis by suppressing HIF-1α/TGF-β-mediated cuproptosis.

Keywords

Myocardial infarction / Dapagliflozin / SGLT2 inhibitor / Cuproptosis / HIF-1α

References

[1] Gabriel-CostaD. The pathophysiology of myocardial infarction-induced heart failure. Pathophysiol., 2018, 25(4): 277-284.

[2] JenčaD, MelenovskýV, StehlikJ, et al.. Heart failure after myocardial infarction: incidence and predictors. ESC Heart Fail., 2021, 8(1): 222-237.

[3] SaitoY, OyamaK, TsujitaK, et al.. Treatment strategies of acute myocardial infarction: updates on revascularization, pharmacological therapy, and beyond. J Cardiol., 2023, 81(2): 168-178.

[4] NiL, YuanC, ChenG, et al.. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol., 2020, 19198.

[5] PanHC, ChenJY, ChenHY, et al.. Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease. JAMA Netw Open., 2024, 71. e2350050

[6] CowieMR, FisherM. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol., 2020, 17(12): 761-772.

[7] PackerM. SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism. Nat Rev Cardiol., 2023, 20(7): 443-462.

[8] JhundPS, KondoT, ButtJH, et al.. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med., 2022, 28(9): 1956-1964.

[9] BhattDL, VermaS, BraunwaldE. The DAPA-HF trial: a momentous victory in the war against heart failure. Cell Metab., 2019, 30(5): 847-849.

[10] ZhaoX, LiuY, HanX, et al.. Dapagliflozin attenuates the vulnerability to atrial fibrillation in rats with lipopolysaccharide-induced myocardial injury. Int Immunopharmacol., 2023, 125. 111038

[11] KarakasisP, FragakisN, KouskourasK, et al.. Sodium-glucose cotransporter-2 inhibitors in patients with acute coronary syndrome: a modern cinderella?. Clin Ther., 2024, 46(11): 841-850.

[12] KarakasisP, PatouliasD, KassimisG, et al.. Therapeutic potential of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with acute coronary syndrome: a review of clinical evidence. Curr Pharm Des., 2024, 30(27): 2109-2119.

[13] ChenL, MinJ, WangF. Copper homeostasis and cuproptosis in health and disease. Signal Transduct Target Ther., 2022, 71378.

[14] XueQ, KangR, KlionskyDJ, et al.. Copper metabolism in cell death and autophagy. Autophagy., 2023, 19(8): 2175-2195.

[15] WangY, ZhangL, ZhouF. Cuproptosis: a new form of programmed cell death. Cell Mol Immunol., 2022, 19(8): 867-868.

[16] XiongC, LingH, HaoQ, et al.. Cuproptosis: p53-regulated metabolic cell death?. Cell Death Differ., 2023, 30(4): 876-884.

[17] FangX, JiY, LiS, et al.. Paeoniflorin attenuates cuproptosis and ameliorates left ventricular remodeling after AMI in hypobaric hypoxia environments. J Nat Med., 2024, 78(3): 664-676.

[18] HuoS, WangQ, ShiW, et al.. ATF3/SPI1/SLC31A1 signaling promotes cuproptosis induced by advanced glycosylation end products in diabetic myocardial injury. Int J Mol Sci., 2023, 2421667.

[19] ShibusawaR, YamadaE, OkadaS, et al.. Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death. Sci Rep., 2019, 919887.

[20] ZhaoY, LiuZ, ZhangH. Astragaloside protects myocardial cells from apoptosis through suppression of the TLR4/NF-κB signaling pathway. Exp Ther Med., 2018, 15(2): 1505-1509

[21] ZhouQ, MengD, LiF, et al.. Inhibition of HIPK2 protects stress-induced pathological cardiac remodeling. eBioMedicine., 2022, 85104274.

[22] GuoY, YuY, HuS, et al.. The therapeutic potential of mesenchymal stem cells for cardiovascular diseases. Cell Death Dis., 2020, 115349.

[23] ZhangM, LiuQ, MengH, et al.. Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther., 2024, 9112.

[24] PagliaroBR, CannataF, StefaniniGG, et al.. Myocardial ischemia and coronary disease in heart failure. Heart Fail Rev., 2020, 25(1): 53-65.

[25] TangD, ChenX, KroemerG. Cuproptosis: a copper-triggered modality of mitochondrial cell death. Cell Res., 2022, 32(5): 417-418.

[26] ChenX, CaiQ, LiangR, et al.. Copper homeostasis and copper-induced cell death in the pathogenesis of cardiovascular disease and therapeutic strategies. Cell Death Dis., 2023, 142105.

[27] TsvetkovP, CoyS, PetrovaB, et al.. Copper induces cell death by targeting lipoylated TCA cycle proteins. Sci., 2022, 375(6587): 1254-1261.

[28] RuizLM, LibedinskyA, ElorzaAA. Role of copper on mitochondrial function and metabolism. Autophagy., 2021, 19(8): 2175-2195

[29] LiuZ, GeX, WangY, et al.. Enhancing the Fenton-like reactions performance of copper-iron oxide by inducing a lower valence state using oxidized g-C3N4 support. Colloids Surf A Physicochem Eng Aspects., 2024, 684. 133135

[30] YfantisA, MylonisI, ChachamiG, et al.. Transcriptional response to hypoxia: the role of HIF-1-associated co-regulators. Cells., 2023, 125798.

[31] LiuD, WangL, HaW, et al.. HIF-1α: a potential therapeutic opportunity in renal fibrosis. Chem Biol Interact., 2024, 387. 110808

[32] Valle-TenneyR, RebolledoD, AcuñaMJ, et al.. HIF-hypoxia signaling in skeletal muscle physiology and fibrosis. J Cell Commun Signal., 2020, 14(2): 147-158.

[33] YanX, ZhaoR, FengX, et al.. Sialyltransferase7A promotes angiotensin II-induced cardiomyocyte hypertrophy via HIF-1α-TAK1 signalling pathway. Cardiovasc Res., 2020, 116(1): 114-126.

[34] SuiX, WeiH, WangD. Novel mechanism of cardiac protection by valsartan: synergetic roles of TGF-β1 and HIF-1α in Ang II-mediated fibrosis after myocardial infarction. J Cell Mol Med., 2015, 19(8): 1773-1782.

Funding

Fujian Provincial Natural Science Foundation of China(2022J011489)

Startup Fund for scientific research of Fujian Medical University(2021QH1210)

RIGHTS & PERMISSIONS

The Author(s), under exclusive licence to Huazhong University of Science and Technology